Your browser doesn't support javascript.
loading
Secretome and immune cell attraction analysis of head and neck cancers.
Muijlwijk, Tara; Wondergem, Niels E; Ekhlas, Fatima; Remkes, Naomi; Nijenhuis, Dennis N L M; Fritz, Lennart; Ganzevles, Sonja H; Miedema, Iris H C; Leemans, C René; Poell, Jos B; Brakenhoff, Ruud H; van de Ven, Rieneke.
Afiliación
  • Muijlwijk T; Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands.
  • Wondergem NE; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
  • Ekhlas F; Amsterdam Institute for Immunology and Infectious Diseases, Cancer Immunology, Amsterdam, Netherlands.
  • Remkes N; Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands.
  • Nijenhuis DNLM; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
  • Fritz L; Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands.
  • Ganzevles SH; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
  • Miedema IHC; Amsterdam Institute for Immunology and Infectious Diseases, Cancer Immunology, Amsterdam, Netherlands.
  • Leemans CR; Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands.
  • Poell JB; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, Netherlands.
  • Brakenhoff RH; Amsterdam Institute for Immunology and Infectious Diseases, Cancer Immunology, Amsterdam, Netherlands.
  • van de Ven R; Otolaryngology/Head and Neck Surgery, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan, 1117-Zh 2A60, 1081 HV, Amsterdam, Netherlands.
Cancer Immunol Immunother ; 73(11): 229, 2024 Sep 09.
Article en En | MEDLINE | ID: mdl-39249543
ABSTRACT
Immune checkpoint inhibitors are approved for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) but the response rate is only 13-18%. For an effective antitumor immune response, trafficking of immune cells to the tumor microenvironment (TME) is essential. We aimed to better understand immune cell migration as well as the involved chemokines in HNSCC. A transwell assay was used to study immune cell migration toward TME-conditioned medium. While T cell migration was not observed, conventional dendritic cell (cDC) migration was induced by TME-conditioned media. cDC migration correlated with various proteins in the TME secretome. CCL8, CXCL5, CCL13 and CCL7 were tested in validation experiments and addition of these chemokines induced cDC migration. Using single cell RNA-sequencing, we observed expression of CCL8, CXCL5, CCL13 and CCL7 in cancer-associated fibroblasts (CAFs). Depleting fibroblasts led to reduced cDC migration. Thus CAFs, while often seen as suppressors of antitumor immunity, play a role in attracting cDCs toward the head and neck cancer TME, which might be crucial for effective antitumor immunity and response to therapies. Indeed, we found RNA expression signatures of the indicated chemokines, cDC and CAF subpopulations, to be significantly higher in baseline tumor specimen of patients with a major pathological response to pre-surgical anti-PD-1 treatment compared to non-responding patients.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Dendríticas / Movimiento Celular / Microambiente Tumoral / Neoplasias de Cabeza y Cuello Límite: Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Células Dendríticas / Movimiento Celular / Microambiente Tumoral / Neoplasias de Cabeza y Cuello Límite: Humans Idioma: En Revista: Cancer Immunol Immunother Asunto de la revista: ALERGIA E IMUNOLOGIA / NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos